Kopran Ltd - Stock Valuation and Financial Performance

BSE: 524280 | NSE: KOPRAN | Pharmaceuticals & Drugs | Small Cap

Kopran Share Price

255.95 8.95 3.62%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Kopran

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Kopran stock performance -

mw4me loader
P/E Ratio (SA):
50.14
Market Cap:
1,245.8 Cr.
52-wk low:
96
52-wk high:
292.4

Is Kopran Ltd an attractive stock to invest in?

1. Is Kopran Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kopran Ltd is a below average quality company.

2. Is Kopran Ltd undervalued or overvalued?

The key valuation ratios of Kopran Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Kopran Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Kopran Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Kopran:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kopran Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 10.7%6.2%8.4%3.9%1.8%6.5%5.7%7.5%3.2%7.8%-
Value Creation
Index
-0.2-0.6-0.4-0.7-0.9-0.5-0.6-0.5-0.8-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 302326187182154197179223205273327
Sales YoY Gr.-7.8%-42.5%-3.1%-15.3%27.9%-8.8%24.3%-8.2%33.5%-
Adj EPS 4.31.62.80.603.12.64.11.86.45.2
YoY Gr.--63.8%80%-77.8%-96.8%15250%-14%54.2%-54.8%249.5%-
BVPS (₹) 3539.643.546.547.650.553.157.178.682.183.1
Adj Net
Profit
16.76.412.12.70.113.311.417.68.93125
Cash Flow from Ops. 1.952.618.74.212.511.81048.8-37.816.9-
Debt/CF from Ops. 68.40.71.813.44.24.24.60.3-11.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -1.1%12.2%15.1%33.5%
Adj EPS 4.6%217.3%34.6%249.5%
BVPS9.9%11.5%15.6%4.4%
Share Price 28.6% 43.8% 36.1% 153%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
12.23.96.31.406.35.17.42.886.2
Op. Profit
Mgn %
14.19.713.39.64.711.813.113.57.510.48.9
Net Profit
Mgn %
5.526.41.50.16.86.47.94.311.47.6
Debt to
Equity
0.90.20.20.30.30.20.20.10.10.1-
Working Cap
Days
228221267188233186229187236231102
Cash Conv.
Cycle
553622548428455878344

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 6.20%

Sales growth is growing at healthy rate in last 3 years 15.06%

Net Profit is growing at healthy rate in last 3 years 34.55%

Sales growth is good in last 4 quarters at 30.51%

No data to display

Latest Financials - Kopran Ltd.

Standalone Consolidated
TTM EPS (₹) 5.2 8.4
TTM Sales (₹ Cr.) 327 577
BVPS (₹.) 83.1 94.8
Reserves (₹ Cr.) 352 409
P/BV 3.11 2.72
PE 50.14 30.85
From the Market
52 Week Low / High (₹) 96.00 / 292.40
All Time Low / High (₹) 6.40 / 558.84
Market Cap (₹ Cr.) 1,246
Equity (₹ Cr.) 48.2
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Kopran:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales302326187182154197179223205273
Operating Expenses 259294162164146174156193189245
Manufacturing Costs39432226283029313739
Material Costs171194103957710286121107156
Employee Cost 23291619182020182125
Other Costs 26282224232121232525
Operating Profit 4332251772323301528
Operating Profit Margin (%) 14.1%9.7%13.3%9.6%4.7%11.5%12.9%13.5%7.5%10.2%
Other Income 1619103210816
Interest 14131010756433
Depreciation 121033333444
Exceptional Items 00-10000000
Profit Before Tax 1715111371716331637
Tax 0005245946
Profit After Tax 171511951311231231
PAT Margin (%) 5.6%4.8%6.1%4.7%3.1%6.6%6.3%10.5%5.7%11.4%
Adjusted EPS (₹)4.43.82.62.01.13.02.65.42.46.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%28%123%46%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 145171197201206218230247379396
Share Capital 48505243434343434848
Reserves 98122145158162175186204331347
Minority Interest0000000000
Debt115262950454136163728
Long Term Debt6382228222210222
Short Term Debt5218722241927133526
Trade Payables35363636293232403062
Others Liabilities 33411819172428221920
Total Liabilities 329275279306297316326324464506

Fixed Assets

Gross Block273788343455156656873
Accumulated Depreciation1704548371013172126
Net Fixed Assets103333539384243474647
CWIP 1004877334
Investments 746156157157158158159259260
Inventories53142825302541284248
Trade Receivables55292038204542495984
Cash Equivalents 5442211333
Others Assets1061483540423933355261
Total Assets 329275279306297316326324464506

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 25319412121049-3817
PBT 1715111371716331637
Adjustment 26221316631274-9
Changes in Working Capital -4115-6-243-5-1414-55-5
Tax Paid 000-1-3-4-4-5-4-6
Cash Flow From Investing Activity -9-10-4-9-2-41-9-10010
Capex -9-11-5-12-5-6-5-4-3-6
Net Investments 01-10000-200
Others 0133415-2-9716
Cash Flow From Financing Activity 7-43-155-11-7-11-40138-26
Net Proceeds from Shares 000000001260
Net Proceeds from Borrowing 000-14000-900
Interest Paid -14-13-10-10-7-5-6-4-3-3
Dividend Paid 0000000-6-6-14
Others 22-30-528-4-2-5-2021-9
Net Cash Flow 0000000001
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)13.3110.346.524.372.316.125.019.853.758.07
ROCE (%)12.4911.449.459.55.288.677.9813.575.649.44
Asset Turnover Ratio11.110.680.620.510.640.560.690.520.56
PAT to CFO Conversion(x)0.123.531.730.442.40.920.912.13-3.170.55
Working Capital Days
Receivable Days61464758696089759796
Inventory Days53374153655168566260
Payable Days8868128137154109134106119107

Kopran Ltd Stock News

Kopran Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Kopran on 28-Mar-2024 16:01 is ₹255.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Kopran stood at ₹1,245.8.
The latest P/E ratio of Kopran as of 28-Mar-2024 16:01 is 50.14.
The latest P/B ratio of Kopran as of 28-Mar-2024 16:01 is 3.11.
The 52-week high of Kopran is ₹292.4 and the 52-week low is ₹96.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kopran is ₹327.1 ( Cr.) .

About Kopran Ltd

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd.  KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

  • Antibiotics/antibacterials
  • Anti-malarial
  • Cadiovasculars
  • Pain management
  • Anthelminthics
  • Antiprotozoals
  • Antidiabetics
  • Gastrointestinals
  • Drug for erectile dysfuntion
  • Antiallergics
  • Respiratory/anti-asthmatics
  • Metered dose inhalers
  • Dry powder inhalers
  • Antiviral

Active Pharmaceutical Ingredients

  • Anti-hypertensives
  • Macrolides
  • Taste Masked
  • Cephalosporins 
  • Under Development
  • Others

Achievements/ recognition:

  • Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

  • Brand Equity Development
  • Research for New Chemical Entities
  • Globalise its operations thus making Kopran a truly International Pharmaceutical Company.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.